CLINICAL TRIALS PROFILE FOR IMMUNE GLOBULIN SUBCUTANEOUS (HUMAN)
✉ Email this page to a colleague
All Clinical Trials for immune globulin subcutaneous (human)
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00424489 ↗ | Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis | Terminated | Northwestern University | Phase 1 | 2002-02-01 | MG may be neonatal, congenital, or autoimmune. Neonatal MG arises from transplacental transfer of ACh receptor antibodies from a mother with autoimmune MG to the fetus. Neonatal MG resolves with post delivery clearance of maternal antibodies. Congenital MG results from a genetic defect in the ACh receptor. Patients with congenital MG do not have ACh receptor antibodies. Both neonatal and congenital MG are excluded from this study. Autoimmune MG, which is the most common form of MG, affects approximately 25,000 Americans. Like most autoimmune diseases, it is associated with particular HLA genotypes, has a female predominance, and environmental factors involved in breaking tolerance to the ACh receptor are unknown. Patients with refractory and severe autoimmune MG will be considered candidates for this study. The purpose of this study is to assess the toxicity/feasibility (phase I) of autologous hematopoietic stem cell transplantation for refractory myasthenia gravis. |
| NCT01218438 ↗ | Phase 2/3 Study of IGSC, 20% in PIDD | Completed | Baxalta now part of Shire | Phase 2/Phase 3 | 2013-01-28 | The purpose of this study is to develop a 20% subcutaneous (SC) immunoglobulin preparation for the treatment of patients with primary immunodeficiency diseases (PIDD). |
| NCT01218438 ↗ | Phase 2/3 Study of IGSC, 20% in PIDD | Completed | Baxalta US Inc. | Phase 2/Phase 3 | 2013-01-28 | The purpose of this study is to develop a 20% subcutaneous (SC) immunoglobulin preparation for the treatment of patients with primary immunodeficiency diseases (PIDD). |
| NCT01856205 ↗ | Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis | Completed | B.P. Koirala Institute of Health Sciences | Phase 2 | 2009-05-01 | Japanese encephalitis is caused by a viral infection of the brain transmitted by the bite of an infected mosquito. Patients with Japanese encephalitis can rapidly develop worsening conscious level and seizures. Around a third will die from the infection and half of survivors have serious long-term neurological disability. The majority of those affected are children. There are many causes of viral encephalitis, however Japanese encephalitis virus is the most common cause worldwide with over 60,000 cases annually. It occurs over much of Asia and the geographical range is expanding. There is no specific treatment for Japanese encephalitis virus, although several have been trialed. In this study we examined the effect of a new treatment, called intravenous immunoglobulin, on children with Japanese encephalitis in Nepal. Prior studies have suggested intravenous immunoglobulin may neutralize Japanese encephalitis virus and suppress damaging inflammation in the brain. It has previously been used in individual cases but never examined in a randomized trial. There was recently a trial of IVIG in West Nile encephalitis in the United States, in which Professor Solomon was on the Scientific Advisory Committee. In this study we will look if intravenous immunoglobulin is safe in this context, and that this treatment may alter the way the immune system manages the infection. Therefore, in this pilot study we will test the hypothesis that IVIG can be safely given to children with suspected JE, with no increased risk of serious adverse events compared with placebo. The aim of this proposal is to conduct a pilot safety and tolerability randomized placebo controlled trial of intravenous immunoglobulin (IVIG) in patients with Japanese encephalitis, to explore the relationship between JEV viral load, pro-inflammatory markers called cytokines and blood brain barrier markers, and the effect of IVIG on these relationships. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for immune globulin subcutaneous (human)
Condition Name
Condition MeSH
Clinical Trial Locations for immune globulin subcutaneous (human)
Trials by Country
Clinical Trial Progress for immune globulin subcutaneous (human)
Clinical Trial Phase
Clinical Trial Sponsors for immune globulin subcutaneous (human)
Sponsor Name
